




Biomedical Photonics Vanderbilt

- NBDG uptake in cell lines responsive to such therapeutics.
- altered.



Metabolic Imaging of Human Breast Carcinoma Treatments Holly D. Thomas¹, Joe T. Sharick², Jason M. Tucker-Schwartz², Melissa C. Skala² ¹Department of Engineering & Physical Science, St. Ambrose University, Davenport, IA, USA

²Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA

Conclusions

- and in vivo applications.

- metabolism.


References

accepted *Sci. USA*. Vol. 89, pp. 1271-1275. Feb. 1992. Photonics, 2014.

microvasculature with multimodal optical coherence tomography." Biomedical Optics Express, 5(6), 1731-1743. doi:10.1364/BOE.5.001731 [7] Moon EJ, Sonveaux P, Porporato PE, Danhier P, Gallez B, et al. (2010) NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment. Proc Natl Acad Sci U S A 107: 20477–20482.

Acknowledgements

- No. NSF DMR-1263182





• Mean fluorescence intensity from two-photon microscopy increases in BT474, MDA-MB-231, and MCF7 breast cancer cells following 2-NBDG incubation.

Cancer therapeutics decrease the 2-NBDG fluorescence intensity in all cell types, thus decreasing glucose uptake.

 2-NBDG fluorescence imaging is a successful method for measuring glucose uptake in human breast carcinoma cells.

• 2-NBDG uptake as a biological marker has the potential to improve the quantification of treatment response in breast cancer.

 Iron oxide-coated gold nanorods are effective in generating photothermal heat and have the potential to be used in mild hyperthermia treatment.

• More work must be done to properly functionalize the gold nanorods for *in vitro*

Future Directions

• Further work will be done to properly functionalize the iron oxide-coated gold nanorods for use *in vitro*. Once the nanorods are functionalized appropriately, fluorescence imaging will measure the effect of the nanorods on cellular

2-NBDG fluorescence imaging will be expanded to three-dimensional organoids with the eventual goal of using fluorescence measurements to determine optimal treatment for breast cancer patients on an individual basis.

[1] AJ Walsh, RS Cook, HC Manning, DJ Hicks, A Lafontant, CL Arteaga, and MC Skala. "Optical metabolic imaging identifies breast cancer glycolytic levels, sub-types, and early treatment response." Cancer Research (2013). Oct 15;73(20):6164-6174. PMID: 24130112

[2] AT Shah, M Demory Beckler, AJ Walsh, WP Jones, PR Pohlmann, and MC Skala. "Optical Metabolic Imaging of Treatment Response in Human Head and Neck Squamous Cell Carcinoma." PLOS ONE (2014)

[3] I. Georgakoudi and K. P. Quinn, "Optical imaging using endogenous contrast to assess metabolic state." Annu Rev Biomed Eng, vol 14, pp 351-67. May 2012.

[4] J. R. Lakowicz, et al. "Fluorescence lifetime imaging of free and protein-bound NADH," Proc. Natl. Acad.

[5] Walsh, Alex J., and Melissa C. Skala. "An automated image processing routine for segmentation of cell cytoplasms in high-resolution autofluorescence images." SPIE BiOS. International Society for Optics and

[6] Tucker-Schwartz, J. M., et al. (2014). "In vivo imaging of nanoparticle delivery and tumor

National Science Foundation (NSF) Research Experience for Undergraduates (REU) Grant

Department of Defense Breast Cancer Research Program (DOD-BCRP)

Optical Imaging Laboratory and Vanderbilt Biomedical Photonics

